Purpose

Establishing tomorrow's standard of care

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life. Our main activities include drug development, drug manufacturing and digital health investment.

 

Debiopharm-history-lake
Your task is not to foresee the future, but to enable it.
Antoine de St-Exupéry

History

For 40 years, we have been driven by the same commitment: bringing innovative solutions to patients

Our story began in 1979 when Dr. Rolland-Yves Mauvernay, convinced that many useful therapeutic products were abandoned before reaching their full potential, decided to establish Debiopharm, a company dedicated to in-licensing innovative compounds and developing them into medicines for out-licensing. Having launched this unique business model with a staff of only 2 people, today, Debiopharm’s 420 employees are now active in a variety of roles within drug development, drug manufacturing and investment in digital health and smart data start-ups.

Together with his son Thierry Mauvernay, they were able to build a team of dedicated professionals with a broad range of expertise. Debiopharm is now a group of three companies active in drug development (Debiopharm International), drug manufacturing (Debiopharm Research & Manufacturing) and digital health investment (Debiopharm Innovation Fund). Debiopharm is the Life Science division of our parent company Après-demain SA, active in asset diversification and philanthropy.

About Apres-demain
Social-Responsibility-Debiopharm
Corporate responsibility

Through corporate responsibility we aim to positively contribute to society and the environment

Learn more
Media Library

Find contact for media inquiries & download corporate resources

Access
Awards and Grants

Each year Debiopharm co-organizes and presents two honors: the JCA-Mauvernay Award and the "Challenge Debiopharm-Inartis" Grant

Discover
Press releases

Latest Debiopharm's announcements for media and journalists

Press Releases